Bullboard - Stock Discussion Forum COSCIENS Biopharma Inc T.CSCI

Alternate Symbol(s): CSCI

Healthcare Biotechnology

COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone... see more

Add To Watchlist

TSX:CSCI - Post Discussion

COSCIENS Biopharma Inc > "fulsome update shortly"

View:

Post by prophetoffactz on Aug 13, 2024 9:03am

"fulsome update shortly"

"fulsome update shortly."

"We are also excited that we remain on track to obtain and announce in Q’3 2024 top-line data from our recently completed Phase 3 safety and efficacy study AEZS-130-P02 (the "DETECT-trial") evaluating macimorelin for the diagnosis of Childhood Onset Growth Hormone Deficiency (“CGHD”),” stated Gilles Gagnon, M.Sc., MBA, President and CEO of COSCIENS."

If the pediatric trial works out as hoped that will help determine how much upfront money CSCI can get from a potential deal(s). That money should help define the business plan for the development of the rest of the portfolio. The diagnostic data is due in the next approximately 33 business days and a fulsome update on the rest of their portfolio is expected "shortly". The portfolio is completing a detailed examination.

411